When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
XLRN - Acceleron's Q3 Results Focus Squarely on Its Celgene Collaboration
Acceleron Pharma Inc.
It's been an up-and-down kind of year so far for Acceleron Pharma(NASDAQ: XLRN). In September, the biotech announced disappointing phase 2 results for ACE-083 in treating facioscapulohumeral muscular dystrophy (FSHD) and scrapped its FSHD program. However, Acceleron's shares have rebounded from this clinical setback in recent weeks.
The company announced its third-quarter results before the market opened on Wednesday, putting that rebound on the line. Here are the highlights from Acceleron's Q3 update.